Publications by authors named "L Svenningsen"
Background & Aims: Clostridioides difficile infection (CDI) is associated with high mortality. Fecal microbiota transplantation (FMT) is an established treatment for recurrent CDI, but its use for first or second CDI remains experimental. We aimed to investigate the effectiveness of FMT for first or second CDI in a real-world clinical setting.
View Article and Find Full Text PDFBackground: Evidence on ustekinumab safety in pregnancy is gradually expanding, but its clearance in the postnatal period is unknown. The aim of this study was to investigate ustekinumab concentrations in umbilical cord blood and rates of clearance after birth, as well as how these correlate with maternal drug concentrations, risk of infection, and developmental milestones during the first year of life.
Methods: Pregnant women with inflammatory bowel disease were prospectively recruited from 19 hospitals in Denmark and the Netherlands between 2018 and 2022.
Introduction: The macrophage activation marker soluble (s)CD163 is associated with disease severity and prognosis in patients with primary biliary cholangitis (PBC). Ursodeoxycholic acid (UDCA) treatment attenuates fibrosis progression in PBC patients, but its effect on macrophage activation is unclear. We examined the effect of UDCA on macrophage activation, as determined by sCD163 levels.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the levels of vedolizumab in umbilical cord blood and its clearance in newborns, focusing on its correlation with maternal drug levels, infection risk, and developmental milestones.
- Out of 50 pregnancies, there were 43 live births with no congenital malformations or significant adverse outcomes, and the ratio of vedolizumab in infants at birth was 0.44.
- Clearance of vedolizumab in infants occurred rapidly, with none showing detectable levels by 6 months, and no increased infection risk was observed in relation to maternal vedolizumab use during pregnancy.
Background: Active inflammatory bowel disease (IBD) adversely affects pregnancy outcomes. Little is known about the risk of relapse after stopping anti-tumor necrosis factor (anti-TNF) treatment during pregnancy. We assessed the risk of relapse before delivery in women who discontinued anti-TNF treatment before gestational week (GW) 30, predictors of reduced infant birth weight, a marker associated with long-term adverse outcomes, and rates and satisfaction with counseling.
View Article and Find Full Text PDF